pentoxifyliine in COVID-19

Phase 2

Recruiting

• Conditions: COVID-19 pneumonia.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20190804044429N4
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Inclusion criteria are adults over the age of 18 with a diagnosis of COVID-19 based on clinical criteria (presence of any symptoms of cough, shortness of breath, fever, and CT scan of the lung for evidence of involvement consistent with COVID-19 infection) or PCR.

Exclusion Criteria

History of allergy to any drugs of therapeutic regimen
pregnancy and lactation
renal and hepatic disease
History of cerebral or ocular bleeding
Glomerular infiltration less than 30 ml / min
History of use of pentoxifylline
Symptoms start more than 14 days before

Study & Design

• Study Type: interventional
• Study Design: Not specified